LENZLENZ Therapeutics, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $19M
- Operating margin
- -477.5%
- EBITDA
- −$91M
- 55% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired66% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $19M | |
| Operating income | −$60M | −$106M | −$72M | −$59M | −$91M | 55% |
| Net income | −$71M | −$101M | −$70M | −$50M | −$82M | 65% |
| Operating cash flow | −$53M | −$88M | −$60M | −$59M | −$69M | 16% |
| Capex | $6M | $7M | $30K | $468K | $827K | 77% |
| Stock-based comp | $8M | $14M | $1M | $6M | $13M | 97% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.